TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

DUEXIS

FAMOTIDINE
Approved 2011-04-23
1
Indication
--
Phase 3 Trials
14
Years on Market

Details

Status
Discontinued
First Approved
2011-04-23
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: FAMOTIDINE , IBUPROFEN

DUEXIS Approval History

Loading approval history...

What DUEXIS Treats

1 FDA approvals

Originally approved for its first indication in 2011 .

  • Other (1)
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DUEXIS FDA Label Details

Pro

DUEXIS Patents & Exclusivity

Latest Patent: Jul 2026

Patents (5 active)

US8067451 Expires Jul 18, 2026
US8501228 Expires Jul 18, 2026
US8318202 Expires Jul 18, 2026
US8309127 Expires Jul 18, 2026
US8449910 Expires Jul 18, 2026
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.